MSD Exec Says Ranbaxy Issue Unlikely To Taint India Drug Makers In U.S.
This article was originally published in PharmAsia News
Merck Sharp & Dohme's emerging-markets president, Kevin Ali, says the U.S. market is not likely to shun drugs made in India just because of the scandal involving Ranbaxy Laboratories.
You may also be interested in...
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.
In a bipartisan move, the US Senate is moving to impose new rules on companies - including those from China - seeking US initial public offerings, adding further uncertainty over such plans and further stoking trade tensions.
First-line lung cancer approval will expand potential market for Takeda's ALK contender but the latecomer is also facing some well-established class competition in the setting.